Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2012 2
2018 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Anesthesia Risks with Semaglutide.
Fezza R, Rains B, Fezza T, Fezza JP. Fezza R, et al. Plast Reconstr Surg Glob Open. 2023 Nov 21;11(11):e5427. doi: 10.1097/GOX.0000000000005427. eCollection 2023 Nov. Plast Reconstr Surg Glob Open. 2023. PMID: 38025626 Free PMC article. No abstract available.
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C. Albini L, et al. Among authors: fezza r. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124. J Acquir Immune Defic Syndr. 2012. PMID: 21992924 Clinical Trial.
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D'Avino A, Focà E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A; ATLAS-M Study Group. Fabbiani M, et al. J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123. J Antimicrob Chemother. 2018. PMID: 29668978 Clinical Trial.
A rare case of severe myopathy associated with etravirine use.
Tommasi C, Tempestilli M, Fezza R, Bellagamba R, Nicastri E, D'offizi G, Pucillo LP, Narciso P. Tommasi C, et al. Among authors: fezza r. AIDS. 2010 Apr 24;24(7):1088-90. doi: 10.1097/QAD.0b013e3283382f65. AIDS. 2010. PMID: 20386384 No abstract available.
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C. Gotti D, et al. Among authors: fezza r. HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245. HIV Clin Trials. 2012. PMID: 23134625
Tolerability of HAART in patients treated during acute HIV infection.
Vlassi C, Corpolongo A, D'Offizi G, Scognamiglio P, Salvatori MF, Fezza R, Narciso P. Vlassi C, et al. Among authors: fezza r. J Acquir Immune Defic Syndr. 2010 Aug;54(5):e11-2. doi: 10.1097/QAI.0b013e3181e3b266. J Acquir Immune Defic Syndr. 2010. PMID: 20647820 No abstract available.